Study guide

1.2 HELLP Syndrome & Hepatic Disorders of Pregnancy

NCC Inpatient Obstetric Nursing RNC-OB

Track your progress as you read

Finished sections get a check mark.

1 Chapter 0: Introduction & How to Use This Guide

0.1 About the RNC-OB Credential & Exam Blueprint 0.2 How to Use This Study Guide & Clinical Learning Methodology

2 Chapter 1: Pregnancy Complications — Maternal Medical Conditions

1.1 Hypertensive Disorders of Pregnancy 1.2 HELLP Syndrome & Hepatic Disorders of Pregnancy 1.3 Diabetes Mellitus in Pregnancy 1.4 Maternal Cardiac and Respiratory Disorders 1.5 Infectious Diseases in Inpatient Obstetrics 1.6 Hematologic, Endocrine, Connective Tissue & Other Systemic Disorders

3 Chapter 2: Pregnancy Complications — Preterm Labor, Multiple Gestation, Placental & Fetal Disorders

2.1 Psychosocial Disorders, Substance Use & Environmental Exposures 2.2 Preterm Labor: Assessment, Tocolysis & Neuroprotection 2.3 Multiple Gestation: Placentation, Chorionicity & Complications 2.4 Placental Disorders: Previa, Abruption, Vasa Previa & PAS 2.5 Fetal Growth Disorders & Amniotic Fluid Complications

4 Chapter 3: Antenatal Fetal Assessment & Surveillance

3.1 Antenatal Testing Methods & Indications for Fetal Surveillance 3.2 Nonstress Test (NST), Contraction Stress Test (CST) & Biophysical Profile (BPP) 3.3 Diagnostic Prenatal Procedures (Amniocentesis, CVS, PUBS, cfDNA & Ultrasound) 3.4 Fetal Oxygenation Physiology & Acid-Base Regulation 3.5 Umbilical Cord Blood Gas Collection & Clinical Interpretation

5 Chapter 4: Fetal Assessment & Electronic Fetal Monitoring (EFM)

4.1 NICHD Electronic Fetal Monitoring Terminology & Baseline Features 4.2 FHR Decelerations, Acceleration Patterns & Uterine Activity 4.3 The NICHD Three-Tier Fetal Heart Rate Classification System 4.4 Intrauterine Resuscitation & Clinical Action Protocols 4.5 Fetal Arrhythmias, Dysrhythmias & Artifact Differentiation

6 Chapter 5: Labor & Birth Physiology — Mechanics, Cardinal Movements, Stages & Support

5.1 Physiology of Labor & Uterine Mechanics 5.2 Pelvic Anatomy, Fetal Lie, Presentation & Cardinal Movements of Labor 5.3 Stages of Labor, Cervical Dilatation Dynamics & Progression Guidelines 5.4 Intrapartum Admission Assessment, Obstetric Triage & Membrane Rupture Evaluation 5.5 Labor Support, Non-Pharmacologic Pain Management & Physiologic Birth Practices

7 Chapter 6: Labor & Birth Interventions — Cervical Ripening, Induction, Pain Management & Anesthesia

6.1 Bishop Scoring, Pre-Induction Cervical Ripening & Mechanical Methods 6.2 Oxytocin Administration, Titration Protocols & Uterine Tachysystole Management 6.3 Nonpharmacologic Comfort & Labor Pain Management Strategies 6.4 Systemic Opioid Analgesia & Inhaled Nitrous Oxide 6.5 Neuraxial Analgesia, Spinal/Epidural Complications & General Anesthesia

8 Chapter 7: Labor & Birth — Operative Deliveries, TOLAC/VBAC & Special Intrapartum Procedures

7.1 External Cephalic Version (ECV) & Malpresentation Management 7.2 Operative Vaginal Delivery: Vacuum Extraction & Forceps-Assisted Birth 7.3 Cesarean Delivery: Surgical Indications, Intraoperative Management & PACU Recovery 7.4 Trial of Labor After Cesarean (TOLAC) & Vaginal Birth After Cesarean (VBAC) 7.5 Special Intrapartum Procedures: Amniotomy, Amnioinfusion, Cervical Ripening & Labor Augmentation

9 Chapter 8: Obstetric Emergencies & Critical Care

8.1 Shoulder Dystocia Management & HELPERR Protocol 8.2 Umbilical Cord Prolapse & Feto-Vascular Emergencies 8.3 Uterine Rupture & Acute Uterine Inversion 8.4 Amniotic Fluid Embolism (Anaphylactoid Syndrome of Pregnancy) 8.5 Intraamniotic Infection (Chorioamnionitis) & Maternal Sepsis

10 Chapter 9: Postpartum Physiology & Immediate Recovery Care

9.1 Postpartum Physiologic Changes & Maternal Systemic Adaptations 9.2 Fourth Stage of Labor & Immediate Recovery Care 9.3 Routine Postpartum Nursing Assessment & Clinical Care (BUBBLE-HE) 9.4 Rh Isoimmunization, Alloimmunization & Postpartum Immunizations 9.5 Postpartum Discharge Teaching, Warning Signs & Maternal Safety

11 Chapter 10: Postpartum Adaptation, Hemorrhage & Clinical Complications

10.1 Postpartum Hemorrhage: Definition, Risk Stratification, 4 Ts, QBL & Pharmacotherapy 10.2 Postpartum Infections: Endometritis, Wound Infections, Sepsis & Postpartum Pyrexia 10.3 Thromboembolic Disorders: DVT, Pulmonary Embolism & Septic Pelvic Thrombophlebitis 10.4 Perinatal Mood & Anxiety Disorders: Postpartum Blues, PPD, Anxiety & Postpartum Psychosis 10.5 Lactation Physiology, Breastfeeding Complications, Engorgement & Medication Safety

12 Chapter 11: Newborn Care, Transition & Clinical Assessment

11.1 Neonatal Physiologic Transition & Cardiorespiratory Adaptation 11.2 Immediate Newborn Care, Apgar Scoring & Delivery Room Stabilization 11.3 Newborn Thermoregulation & Pathophysiology of Cold Stress 11.4 Gestational Age & Neonatal Growth Assessment 11.5 Comprehensive Newborn Head-to-Toe Examination & Normal Variants

13 Chapter 12: Newborn Complications, Resuscitation & High-Acuity Management

12.1 Neonatal Resuscitation Program (NRP 8th Edition) & Delivery Room Resuscitation 12.2 Neonatal Glucose Homeostasis, Hypoglycemia Screening & Clinical Management 12.3 Neonatal Hyperbilirubinemia, Bilirubin Metabolism & Phototherapy Protocols 12.4 Neonatal Respiratory Distress: TTN, RDS, Meconium Aspiration & Persistent Pulmonary Hypertension (PPHN) 12.5 Neonatal Sepsis, Congenital Infections & Neonatal Abstinence Syndrome (NAS/NOWS)

14 Chapter 13: Professional Practice, Legal-Ethical Frameworks, Patient Safety & Quality Improvement

13.1 Legal Aspects of Perinatal Nursing & High-Risk Documentation Standards 13.2 Ethical Principles in Perinatal Care & Maternal-Fetal Conflicts 13.3 Quality Improvement, Perinatal Safety Initiatives & AIM Bundles 13.4 Patient Safety Culture, Team Communication & Clinical Escalation 13.5 Evidence-Based Practice, Research Utilization & Perinatal Guidelines

1.2 HELLP Syndrome & Hepatic Disorders of Pregnancy

Key Takeaways Explain This Topic AI

HELLP syndrome is defined by the laboratory triad of microangiopathic Hemolysis (schistocytes on blood smear, total bilirubin ≥1.2 mg/dL, LDH >600 U/L), Elevated Liver enzymes (AST and ALT ≥2 times upper limit of normal), and Low Platelets (<100,000/μL).

The Mississippi Triple-Class System classifies HELLP based on the nadir platelet count: Class 1 (platelets ≤50,000/μL, AST/ALT ≥70 U/L, LDH >600 U/L), Class 2 (platelets 50,001-100,000/μL), and Class 3 (platelets 100,001-150,000/μL, AST/ALT ≥40 U/L, LDH >600 U/L).

Acute Fatty Liver of Pregnancy (AFLP) is a life-threatening obstetric emergency linked to fetal long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, diagnosed by the Swansea criteria (≥6 required) and characterized by profound refractory hypoglycemia, hyperammonemia, elevated uric acid, and coagulopathy/DIC.

Intrahepatic Cholestasis of Pregnancy (ICP) presents with intense pruritus without primary rash, primarily on palms and soles with nocturnal exacerbation; diagnosis is confirmed by elevated total serum bile acids (TBA ≥10 μmol/L), treated with first-line ursodeoxycholic acid (UDCA), and delivered at 36 0/7 to 39 0/7 weeks (or at 36 0/7 weeks if TBA ≥100 μmol/L).

Platelet transfusion is indicated in HELLP syndrome prior to delivery if platelet count is <20,000/μL for vaginal delivery or <50,000/μL for cesarean delivery; neuraxial anesthesia is generally avoided when platelets are <70,000-80,000/μL or rapidly falling.

Last updated: August 2026

Pathophysiology and Clinical Manifestation of HELLP Syndrome

HELLP syndrome is a severe, life-threatening manifestation of systemic endothelial injury that occurs in approximately 0.5% to 0.9% of all pregnancies and in 10% to 20% of women with severe preeclampsia. Crucially, up to 15% to 20% of patients with HELLP syndrome do not exhibit antecedent hypertension or proteinuria, frequently leading to delayed diagnosis or misdiagnosis as acute cholecystitis, gastroenteritis, or viral hepatitis.

The syndrome represents an acronym defining its core laboratory triad:

H (Hemolysis): Microangiopathic hemolytic anemia resulting from the mechanical fragmentation of erythrocytes as they are forced at high pressure through constricted, damaged vascular beds lined with meshworks of fibrin strands.

EL (Elevated Liver Enzymes): Obstruction of hepatic sinusoidal blood flow by microvascular fibrin deposits, leading to localized hepatocyte ischemia, cellular swelling, periportal necrosis, and capsular distension.

LP (Low Platelets): Accelerated consumption and destruction of platelets at widespread sites of endothelial damage, far exceeding the bone marrow's megakaryocyte compensatory capacity.

Clinical Presentation and Warning Signs

The onset of HELLP syndrome is typically insidious, with rapid escalation over 24 to 48 hours. Patients characteristically present with:

Right Upper Quadrant (RUQ) or Epigastric Pain (85–90%): Caused by microvascular congestion and stretching of the hepatic Glisson's capsule. Pain is frequently described as constant, aching, or throbbing, and may radiate to the right flank, back, or right shoulder.

Malaise, Nausea, and Vomiting (50–60%): Often mistaken for viral gastroenteritis or reflux.

Edema and Sudden Weight Gain (60%): Resulting from generalized capillary leakage.

Visual Symptoms and Headache (30–60%): Reflecting cerebral endothelial involvement. +-------------------------------------------------------------------------------------------------------------------+

| HELLP SYNDROME DIAGNOSTIC CRITERIA |

+-------------------------------------------------------------------------------------------------------------------+

  • Diagnostic Component Laboratory Parameter / Diagnostic Threshold
  • ------------------- -------------------------------------------------------------------------------------
  • 1. HEMOLYSIS (H) - Abnormal peripheral blood smear demonstrating Schistocytes, Burr cells, or Helmet cells
  • Serum Lactate Dehydrogenase (LDH) >600 U/L
  • Total Serum Bilirubin ≥1.2 mg/dL (predominantly indirect/unconjugated)
  • Low or undetectable serum Haptoglobin (<25 mg/dL)

-------------------------------------------------------------------------------------------------------------------

  • 2. ELEVATED LIVER - Serum Aspartate Aminotransferase (AST) ≥70 U/L (or ≥2 times upper limit of normal)
  • ENZYMES (EL) - Serum Alanine Aminotransferase (ALT) ≥2 times upper limit of normal

-------------------------------------------------------------------------------------------------------------------

3. LOW PLATELETS (LP) - Platelet count <100,000/μL (severe thrombocytopenia)

+-------------------------------------------------------------------------------------------------------------------+

Classification Systems

Two validated systems are utilized in clinical practice:

Tennessee Classification (Strict Criteria): Complete HELLP requires all three components: microangiopathic hemolysis (LDH >600 U/L, abnormal smear), AST ≥70 U/L, and platelets <100,000/μL. Partial or incomplete HELLP (ELLP or HEL) carries similar maternal risk and mandates identical aggressive management.

Mississippi Triple-Class System (Prognostic Stratification):

Class 1 (Severe): Platelets ≤50,000/μL; LDH >600 U/L; AST/ALT ≥70 U/L. Highest risk of maternal mortality, DIC, renal failure, and hepatic hematoma.

Class 2 (Moderate): Platelets >50,000 to ≤100,000/μL; LDH >600 U/L; AST/ALT ≥70 U/L.

Class 3 (Mild / Resolving): Platelets >100,000 to ≤150,000/μL; LDH >600 U/L; AST/ALT ≥40 U/L.

Hepatic Catastrophes: Subcapsular Hematoma and Rupture

A catastrophic complication of HELLP syndrome is the development of a hepatic subcapsular hematoma and subsequent hepatic parenchymal rupture, occurring in 1% to 2% of HELLP cases. Extensive sinusoidal thrombosis leads to localized parenchymal infarction, intrahepatic hemorrhage, and progressive dissection of blood beneath Glisson's capsule. Rupture occurs when intra-capsular pressure exceeds the structural integrity of the capsule.

Clinical Presentation of Hepatic Rupture

Sudden, tearing, excruciating RUQ pain radiating into the right shoulder (phrenic nerve irritation / Kehr's sign).

Sudden profound maternal hypotension, hypovolemic shock, pallor, diaphoresis, and cardiovascular collapse.

Acute abdominal distension and peritoneal signs (rebound tenderness, rigidity).

Urgent Nursing and Surgical Interventions

Immediate Hemodynamic Resuscitation: Place two large-bore IV lines (14- or 16-gauge) or central venous access; activate the hospital Massive Transfusion Protocol (MTP) immediately.

Urgent Diagnostic Imaging: Bedside Focused Assessment with Sonography for Trauma (FAST) or emergency abdominal CT scan (if hemodynamically stable enough) to visualize free intra-abdominal fluid and hepatic parenchymal disruption.

Emergent Surgical Intervention: Immediate exploratory laparotomy with an interdisciplinary surgical team (maternal-fetal medicine, trauma/transplant surgery). Surgical management includes hepatic packing, primary surgical ligation, application of topical hemostatic agents, or transcatheter hepatic arterial embolization (TAE).

Correction of Coagulopathy: Rapid transfusion of packed red blood cells, fresh frozen plasma (FFP), cryoprecipitate (to maintain fibrinogen >200 mg/dL), and platelets.

Acute Fatty Liver of Pregnancy (AFLP)

Acute Fatty Liver of Pregnancy (AFLP) is an uncommon (1 in 10,000 to 1 in 20,000 pregnancies) but catastrophic obstetric emergency characterized by microvesicular fatty infiltration of hepatocytes, culminating in acute maternal liver failure, encephalopathy, and disseminated intravascular coagulation. It typically presents in the late third trimester (30–38 weeks) or early postpartum period.

Pathophysiology and Genetics

AFLP is strongly associated with an inherited fetal defect in mitochondrial fatty acid beta-oxidation, specifically a deficiency in long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) (most commonly the G1528C mutation). The heterozygous mother cannot adequately metabolize the excessive load of intermediate long-chain fatty acids produced by the homozygous LCHAD-deficient fetus and placenta, causing toxic accumulation of free fatty acids in maternal hepatocytes, which disrupts mitochondrial energy production.

Diagnostic Criteria: The Swansea Diagnostic Criteria

The diagnosis of AFLP is established clinically using the Swansea Criteria ; the presence of 6 or more criteria in the absence of an alternative explanation confirms AFLP: +-------------------------------------------------------------------------------------------------------------------+

| SWANSEA CRITERIA FOR AFLP (≥6 REQUIRED) |

+-------------------------------------------------------------------------------------------------------------------+

  • Clinical Findings Laboratory & Imaging Findings
  • ---------------- -----------------------------
  • 1. Vomiting 6. Total Bilirubin >14 μmol/L (>0.8 mg/dL)
  • 2. Abdominal pain (Epigastric/RUQ) 7. Hypoglycemia <4.0 mmol/L (<72 mg/dL) [PROFOUND / REFRACTORY]
  • 3. Polydipsia / Polyuria (DI) 8. Elevated Serum Uric Acid >340 μmol/L (>5.7 mg/dL)
  • 4. Hepatic Encephalopathy (Asterixis) 9. Leukocytosis (WBC >11.0 x 10^9/L)
  • 5. Microvesicular steatosis on biopsy 10. Elevated Transaminases (AST or ALT >42 U/L)
  • 11. Hyperammonemia (>47 μmol/L) [Causes Encephalopathy]
  • 12. Renal Impairment (Creatinine >150 μmol/L or >1.7 mg/dL)
  • 13. Coagulopathy (PT >14 seconds or aPTT >34 seconds, low Fibrinogen)
  • 14. Bright liver or ascites on ultrasound / CT

+-------------------------------------------------------------------------------------------------------------------+

Critical Clinical Distinctions: AFLP vs. HELLP

While both disorders present with RUQ pain and elevated transaminases, AFLP is uniquely distinguished by:

Profound, refractory hypoglycemia (blood glucose often <50 mg/dL) due to impaired hepatic gluconeogenesis and glycogenolysis; requires continuous IV 10% or 20% dextrose infusions.

Marked Coagulopathy / Prolonged PT/INR and aPTT occurring early in the disease process prior to delivery, whereas HELLP primarily features thrombocytopenia with preserved coagulation times until advanced DIC develops.

Hyperammonemia and Encephalopathy with asterixis, confusion, and lethargy.

Diabetes Insipidus (polydipsia, polyuria) secondary to decreased hepatic clearance of placental vasopressinase.

Intrahepatic Cholestasis of Pregnancy (ICP)

Intrahepatic Cholestasis of Pregnancy (ICP) is the most common gestational liver disorder, affecting 0.5% to 2% of pregnancies. It is caused by genetic susceptibility in hepatocellular bile acid transport proteins (e.g., ABCB4/MDR3 mutations) coupled with elevated circulating levels of estrogen and progesterone metabolites, which inhibit bile acid export from hepatocytes into the biliary canaliculus.

Clinical Presentation and Laboratory Diagnosis

Pruritus (Hallmark): Intense, relentless itching characteristically localized to the palms of the hands and soles of the feet , with pronounced nocturnal worsening leading to severe sleep deprivation. Importantly, there is NO primary dermatologic rash (excoriations and scratch marks are secondary to intense itching).

Jaundice (10–15%): Typically develops 1 to 4 weeks after the onset of pruritus.

Total Serum Bile Acids (TBA): The definitive diagnostic test. A fasting or postprandial TBA ≥10 μmol/L confirms the diagnosis.

Risk Stratification and Fetal Risks

Elevated maternal bile acids cross the placenta and accumulate in the fetal compartment, causing direct fetal toxicity:

Mild Cholestasis: TBA 10 to 39 μmol/L (low risk of fetal mortality).

Moderate Cholestasis: TBA 40 to 99 μmol/L.

Severe Cholestasis: TBA ≥100 μmol/L (highest risk; associated with a dramatic surge in sudden intrauterine fetal demise, spontaneous preterm birth, and meconium aspiration).

Fetal demise in ICP is sudden and unpredictable, resulting from acute bile acid-induced fetal cardiac dysrhythmias (conduction block) or sudden acute vasospasm of placental chorionic surface vessels. Standard antepartum testing (non-stress tests, biophysical profiles) does NOT reliably predict or prevent sudden stillbirth in severe ICP.

Pharmacologic Management and Delivery Timing

First-Line Pharmacotherapy: Ursodeoxycholic Acid (UDCA / Actigall): 10 to 15 mg/kg/day orally (typically 300 mg BID or TID, up to 600–900 mg TID). UDCA is a hydrophilic bile acid that displaces cytotoxic hydrophobic bile acids, enhances biliary export, relieves maternal pruritus within 1–2 weeks, and normalizes serum transaminases and bile acid levels.

Delivery Timing Protocol (ACOG / SMFM Guidelines):

TBA 10 to 39 μmol/L (Mild): Delivery at 36 0/7 to 39 0/7 weeks of gestation .

TBA 40 to 99 μmol/L (Moderate): Delivery at 36 0/7 to 39 0/7 weeks of gestation (often individualized around 36–37 weeks).

TBA ≥100 μmol/L (Severe): Planned delivery at 36 0/7 weeks of gestation (or upon diagnosis if diagnosed later) due to the steep increase in stillbirth risk beyond 36 weeks.

Differential Diagnosis of Hepatic Disorders in Pregnancy

Feature HELLP Syndrome Acute Fatty Liver (AFLP) Intrahepatic Cholestasis (ICP) Acute Cholecystitis

Gestational Age 27 weeks to 48h postpartum Late 3rd trimester to postpartum Late 2nd to 3rd trimester Any trimester

Primary Symptoms RUQ pain, nausea, malaise, edema Vomiting, abdominal pain, polydipsia, confusion Intense palmar/plantar pruritus without rash Colicky RUQ pain after fatty meals, Murphy's sign

Blood Pressure Usually elevated (80-85%) Variable / Normal Normal Normal

Transaminases (AST/ALT) Elevated (≥70 to >1000 U/L) Elevated (100–1000 U/L) Mildly elevated (2–5x ULN) Mildly elevated or normal

  • Platelet Count Severely Low (<100,000/μL) Low to Normal (consumptive) Normal Normal
  • Coagulation (PT/aPTT) Normal until advanced DIC Markedly Prolonged early Normal Normal
  • Serum Glucose Normal Profound Hypoglycemia (<50) Normal Normal
  • Serum Bile Acids Normal or mildly elevated Moderately elevated Elevated (≥10 to >100 μmol/L) Normal

Primary Treatment Immediate delivery, M g S O 4 MgSO_4 M g S O 4 ​ , antihypertensives Immediate delivery, IV glucose, ICU supportive care Ursodeoxycholic acid, planned delivery 36–39 wk Bowel rest, IV fluids, IV antibiotics, cholecystectomy

Inpatient Nursing Priorities for HELLP and Acute Hepatic Disease

Hemodynamic and Neurologic Surveillance: Continuous blood pressure monitoring, seizure prophylaxis with IV magnesium sulfate (4-6 g load, 1-2 g/hr maintenance), hourly assessment of DTRs, clonus, and mental status.

Serial Laboratory Monitoring: Stat CBC with platelet count, comprehensive metabolic panel (AST, ALT, creatinine, bilirubin), LDH, fibrinogen, PT/INR, and aPTT drawn every 6 to 12 hours until clear improvement is demonstrated postpartum.

Platelet Transfusion Protocols:

Platelet count <20,000/μL: Transfuse 1 apheresis unit of platelets immediately, regardless of delivery mode.

Platelet count <50,000/μL: Transfuse platelets prior to planned cesarean delivery.

Platelets <70,000–80,000/μL: Neuraxial anesthesia (spinal/epidural) is contraindicated due to the risk of epidural hematoma and spinal cord compression. General anesthesia is typically required for cesarean birth.

Postpartum Course Anticipation: Maternal laboratory parameters characteristically worsen during the first 24 to 48 hours postpartum, with the nadir of thrombocytopenia and peak of LDH occurring at 24 to 48 hours post-delivery . Clinical recovery, signaled by an upward trend in platelet count (>100,000/μL) and downward trend in transaminases, typically begins by postpartum day 3 to 4.